期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (4)
The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the global economy and strained healthcare systems to their limits. Afte......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (8)
Background Hepatocellular carcinoma (HCC) is characterized by inflammation and immunopathogenesis. Accumulating evidence has shown that the cystathion......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (7)
Background Despite PD-L1 (Programmed death receptor ligand-1) expression on tumor cells and cytotoxic T lymphocytes tumor infiltration in the tumor mi......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (8)
Background Although immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis bloc......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (6)
Background Tumors rewire their metabolism to achieve robust anabolism and resistance against therapeutic interventions like cisplatin treatment. For e......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (8)
Background Cancer vaccines are a promising strategy for cancer immunotherapy. Cancer vaccines elicits a specific cytotoxic immune response to tumor an......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (7)
Background Death receptor 5 (DR5) is a promising therapeutic target for cancer therapy. However, many clinical trials of DR5 agonists failed to show s......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (7)
Background Stimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibito......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (4)
Background High-grade gliomas are rapidly progressing tumors of the central nervous system, and are associated with poor prognosis and highly immunosu......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (7)
Background Tryptophan catabolites suppress immunity. Therefore, blocking tryptophan catabolism with indoleamine 2,3-dioxygenase (IDO) inhibitors is pu......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (6)
Background The discovery of checkpoint inhibitors towards cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has bee......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (8)
Background The abnormal upregulation of programmed death-ligand 1 (PD-L1) in cancer cells inhibits T cell-mediated cytotoxicity, but the molecular mec......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (5)
Background Autologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 molecule have transformed the therapeutic land......
期刊： JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (4)
Background In the tumor microenvironment, tumor cells are able to suppress antitumor immunity by competing for essential nutrients, including amino ac......
